A Ten-year Retrospective Study of Invasive Candidiasis in a Tertiary Hospital in Beijing

被引:6
作者
Yang Zhi Hui
Song Ying Gai
Li Ruo Yu [1 ]
机构
[1] Peking Univ First Hosp, Dept Dermatol & Venerol, Beijing 100034, Peoples R China
关键词
Invasive candidiasis; Epidemiology; Risk factors; Antifungal resistance; Treatment; Mortality; BLOOD-STREAM INFECTIONS; INTENSIVE-CARE UNITS; SPECIES DISTRIBUTION; ANTIFUNGAL SUSCEPTIBILITY; RISK-FACTORS; CLINICAL-FEATURES; EPIDEMIOLOGY; (1,3)-BETA-D-GLUCAN; COLONIZATION; CANDIDEMIA;
D O I
10.3967/bes2021.107
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Objective This study aimed to evaluate the epidemiological, clinical and mycological characteristics of invasive candidiasis (IC) in China. Methods A ten-year retrospective study including 183 IC episodes was conducted in a tertiary hospital in Beijing, China. Results The overall incidence of IC from 2010-2019 was 0.261 episodes per 1,000 discharges. Candidemia (71.0%) was the major infective pattern; 70.3% of the patients tested positive for Candida spp. colonization before IC and the median time to develop an invasive infection after colonization was 13.5 days (interquartile range: 4.5-37.0 days). Candida albicans (45.8%) was the most prevalent species, followed by Candida parapsilosis (19.5%), Candida glabrata (14.2%) and Candida tropicalis (13.7%). C. non-albicans IC was more common in patients with severe anemia (P = 0.018), long-term hospitalization (P = 0.015), hematologic malignancies (P = 0.002), continuous administration of broad-spectrum antibiotics (P < 0.001) and mechanical ventilation (P = 0.012). In vitro resistance testing showed that 11.0% of the Candida isolates were resistant/non-wild type (non-WT) to fluconazole, followed by voriconazole (9.6%), micafungin (3.8%), and caspofungin (2.9%). Fluconazole was the most commonly used drug to initiate antifungal therapy both before and after the proven diagnosis (52.6% and 54.6%, respectively). The 30-day and 90-day all-cause mortality rates were 24.5% and 32.7%, respectively. Conclusion The incidence of IC has declined in the recent five years. C. non-albicans contributed to more than half of the IC cases. Fluconazole can be used as first-line therapy if resistant strains are not prevalent. Prospective, multi-center surveillance of the clinical and mycological characteristics of IC is required.
引用
收藏
页码:773 / 788
页数:16
相关论文
共 40 条
  • [21] Clinical value of (1,3)-β-D-glucan, mannan, antimannan IgG and IgM antibodies in diagnosis of invasive candidiasis
    Li, Fengtian
    Yu, Xiaotian
    Ye, Liyan
    Zhou, Guang
    Wang, Leili
    Luo, Yanping
    [J]. MEDICAL MYCOLOGY, 2019, 57 (08) : 976 - 986
  • [22] Nosocomial Bloodstream Infection Due to Candida spp. in China: Species Distribution, Clinical Features, and Outcomes
    Li, Ying
    Du, Mingmei
    Chen, Liang-an
    Liu, Yunxi
    Liang, Zhixin
    [J]. MYCOPATHOLOGIA, 2016, 181 (7-8) : 485 - 495
  • [23] Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study
    Liu, Wei
    Tan, Jingwen
    Sun, Jimei
    Xu, Zhijiang
    Li, Min
    Yang, Qing
    Shao, Haifeng
    Zhang, Liyan
    Liu, Weixia
    Wan, Zhe
    Cui, Wei
    Zang, Bin
    Jiang, Dongpo
    Fang, Qiang
    Qin, Bingyu
    Qin, Tiehe
    Li, Weiqin
    Guo, Fengmei
    Liu, Dawei
    Guan, Xiandong
    Yu, Kaijiang
    Qiu, Haibo
    Li, Ruoyu
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (01) : 162 - 167
  • [24] Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit
    Lo Cascio, G.
    Koncan, R.
    Stringari, G.
    Russo, A.
    Azzini, A.
    Ugolini, A.
    Ligozzi, M.
    Polati, E.
    Cornaglia, G.
    Concia, E.
    Schweiger, V.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2015, 34 (02) : 357 - 365
  • [25] Invasive candidiasis
    Pappas, Peter C.
    Lionakis, Michail S.
    Arendrup, Maiken Cavling
    Ostrosky-Zeichner, Luis
    Kullberg, Bart Jan
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2018, 4
  • [26] Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
    Pappas, Peter G.
    Kauffman, Carol A.
    Andes, David R.
    Clancy, Cornelius J.
    Marr, Kieren A.
    Ostrosky-Zeichner, Luis
    Reboli, Annette C.
    Schuster, Mindy G.
    Vazquez, Jose A.
    Walsh, Thomas J.
    Zaoutis, Theoklis E.
    Sobel, Jack D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2016, 62 (04) : 409 - 417
  • [27] Epidemiology of invasive candidiasis: a persistent public health problem
    Pfaller, M. A.
    Diekema, D. J.
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2007, 20 (01) : 133 - +
  • [28] Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)
    Pfaller, Michael A.
    Messer, Shawn A.
    Moet, Gary J.
    Jones, Ronald N.
    Castanheira, Mariana
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 38 (01) : 65 - 69
  • [29] Invasive candidiasis Risk factor for mortality in a pediatric tertiary care hospital in south of Brazil
    Rodrigues, Luiza Souza
    Motta, Fabio Araujo
    Picharski, Gledson Luiz
    Vasconcelos, Thais Muniz
    Riccieri, Marinei Campos
    Dalla-Costa, Ubera Maria
    [J]. MEDICINE, 2019, 98 (23)
  • [30] Prevalence and Antifungal Susceptibility of Pathogenic Yeasts in China: A 10-Year Retrospective Study in a Teaching Hospital
    Song, Yinggai
    Chen, Xianlian
    Yan, Yan
    Wan, Zhe
    Liu, Wei
    Li, Ruoyu
    [J]. FRONTIERS IN MICROBIOLOGY, 2020, 11